2006;12:2879C2887
2006;12:2879C2887. rituximab, multiple research have evaluated the experience of the and various other mAbs, either by itself or in conjunction with chemotherapeutic backbones, for the treating B-cell malignancies. On binding to Compact disc20, rituximab induces antibody-dependent mobile cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis of CLL sensitizes and cells1C3 malignant B cells to chemotherapy.4 The […]
Recent Comments